Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 10 of 10 matching drugs for GPD1 — including drugs targeting any of its 72 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone GPD1 Direct 3
metformin GPD1 Direct 2
gemcitabine, metformin, placebo GPD1 Direct 1
gemcitabine, nab-paclitaxel, folfirinox, immunohistochemistry (ihc) analysis, metformin, mfolfiri GPD1 Direct 1
ketogenic diet, metformin GPD1 Direct 1
levonorgestrel, metformin GPD1 Direct 1
metformin, radiation imrt, temozolomide GPD1 Direct 1
paclitaxel, metformin GPD1 Direct 1
paxalisib, metformin, ketogenic diet GPD1 Direct 1
vitamin c, metformin GPD1 Direct 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.